ClinicalTrials.gg
RecruitingNCT07564141RAINFOL™-07Updated Nov 4, 2026

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

A Phase 3 interventional study of Rina-S and Bevacizumab in Platinum-Sensitive Ovarian Cancer and Ovarian Cancer, sponsored by Genmab. Recruiting at 12 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Genmab · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 4, 2026First sites in Japan and Finland10 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
688
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
70th of 1,498
688 · median 47
Started
2026
with 64 others
Phase 3
103 of 1,779
18 open now
Primary completion
2029-12
later than 391 of 452 live
Registered
1,747th of 1,779
by date

Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 70th largest by planned enrollment of the 1,498 interventional ones that give a count, is one of 65 that started in 2026, is one of 103 in phase 3, reaches primary completion later than 391 of the 452 other live ones, and was the 1,747th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

272 more — sign in →

All 278 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,779 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This Phase 3 study will be conducted in different countries around the world with up to about 688 participants.

The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with or without bevacizumab and how it compares to an investigator's choice of platinum-based chemotherapy with or without bevacizumab.

Participants will receive either:

  • Rina-S monotherapy (by itself),
  • Rina-S plus bevacizumab,
  • investigator's choice chemotherapy (by itself) (standard of care), or
  • investigator's choice chemotherapy plus bevacizumab (standard of care).

No participants will be given placebo. Participants will participate in 1 of 2 arms.

The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.

Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 or 4 weeks, depending on medication received). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective.

The overall study duration (including screening, treatment, and follow-up) will be different for every participant.

Read the detailed description

This is a global, open-label, randomized, Phase 3 study of Rina-S ± bevacizumab versus investigator's choice (IC) ± bevacizumab as second-line (2L) treatment in participants with recurrent platinum-sensitive ovarian cancer (PSOC).

03

Conditions studied

  • Platinum-Sensitive Ovarian Cancer
  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant must have confirmed high-grade serous or endometrioid epithelial ovarian cancer (EOC), including primary peritoneal or fallopian tube cancer.
  • Participant must have documented recurrence or progression after (1L) platinum-based chemotherapy regimen (carboplatin + paclitaxel ≥ 4 cycles) with or without bevacizumab and have platinum-sensitive disease defined as radiographic progression at least 6 months (ie, >183 days) after their last dose administration of platinum-based therapy.
  • Prior poly (ADP-ribose) polymerase inhibitor(s) (PARPi) maintenance therapy (alone or in combination with bevacizumab) is required for participants with breast cancer susceptibility gene (BRCA 1- and BRCA 2)-mutated (germline or somatic) or homologous recombination deficiency (HRD)-positive disease.
  • Participants must have per v1.1 by investigator at baseline.
  • All participants must provide a tumor specimen.
  • Participants must have (ECOG) performance status of 0 or 1 at baseline.

Key Exclusion Criteria:

  • Participants with clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade/borderline ovarian tumors.
  • Participant has received previous therapy with other anti-angiogenetic agents different from bevacizumab or biosimilar.
  • Participant has received prior therapy with an antibody-drug conjugate (ADC) containing a topoisomerase-1 inhibitor.
  • Participant has received prior therapy with an ADC targeting folate receptor alpha (FRα).

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
688 participants (estimated)

Study arms

  • Experimental
    Arm 1: Rina-S ± Bevacizumab

    Participants will receive Rina-S ± bevacizumab once every 3 weeks (Q3W).

    Biological: Rina-S · Drug: Bevacizumab

  • Active comparator
    Arm 2: Investigator Choice of Chemotherapy ± Bevacizumab

    Participants will receive carboplatin plus gemcitabine ± bevacizumab, carboplatin plus paclitaxel ± bevacizumab, or carboplatin plus pegylated liposomal doxorubicin (PLD) ± bevacizumab.

    Drug: Bevacizumab · Drug: Carboplatin · Drug: Gemcitabine · Drug: Paclitaxel · Drug: PLD

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR)

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to approximately 5 years

  2. PFS per RECIST v1.1, as Determined by Investigator

    Time frame: Up to approximately 3 years

  3. Objective Response Rate (ORR) per RECIST v1.1

    Time frame: Up to approximately 3 years

  4. Duration of Response (DOR) per RECIST v1.1

    Time frame: Up to approximately 3 years

  5. Progression-free Survival on the Next Line of Therapy After the First Progression (PFS2)

    Time frame: Up to approximately 3 years

  6. Time to First Subsequent Therapy (TFST)

    Time frame: Up to approximately 3 years

  7. Cancer Antigen 125 (CA-125) Response per Gynecologic Cancer Intergroup (GCIG) Criteria

    Time frame: Up to approximately 3 years

  8. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 3 years

  9. Overall Change from Baseline in Global Health Status (GHS)/Quality of Life (QoL) Score Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30)

    Time frame: Baseline up to approximately 3 years

  10. Time to Deterioration (TTD) in the GHS/QoL Score Using the EORTC QLQ C30 Questionnaire

    Time frame: Up to approximately 3 years

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2029, 40 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 40 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 4, 2026
StartActual
Aug 28, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Nov 2031
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added — first sites in Japan and Finland
Show 10 added (5 United States, 4 Japan, 1 Finland)
  • City of Hope · Duarte, United States
  • Compass Oncology - West Cancer Center (Northwest Cancer Specialists, P.C.) · Tigard, United States
  • Alliance Cancer Specialists, PC · Bensalem, United States
  • West Virginia University · Morgantown, United States
  • The Cancer Institute Hospital of JFCR · Tokyo, Japan
  • Niigata Cancer Center Hospital · Chuo Ku Niigata, Japan
  • Yamagata University Hospital · Yamagata, Japan
  • Utah Cancer Specialists · South Jordan, United States
  • Tampere University Hospital · Tampere, Finland
  • Tokushima University Hospital · Tokushima, Japan
across 2 updates, Oct 7, 2026 – Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    3 sites added — first site in Finland
    Show 3 added (1 United States, 1 Finland, 1 Japan)
    • Utah Cancer Specialists · South Jordan, United States
    • Tampere University Hospital · Tampere, Finland
    • Tokushima University Hospital · Tokushima, Japan
  2. Oct 7, 2026
    7 sites added — first site in Japan
    Show 7 added (4 United States, 3 Japan)
    • City of Hope · Duarte, United States
    • Compass Oncology - West Cancer Center (Northwest Cancer Specialists, P.C.) · Tigard, United States
    • Alliance Cancer Specialists, PC · Bensalem, United States
    • West Virginia University · Morgantown, United States
    • The Cancer Institute Hospital of JFCR · Tokyo, Japan
    • Niigata Cancer Center Hospital · Chuo Ku Niigata, Japan
    • Yamagata University Hospital · Yamagata, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07564141
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Aug 28, 2026
Primary completion
Dec 2029 (estimated)
Completion
Nov 2031 (estimated)
Last update
Nov 4, 2026

Study contacts

Genmab Trial Information
Contact
clinicaltrials@genmab.com
+4570202728
Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rinatabart sesutecan

Start the discussion